A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
Trial details
- Registry ID
- NCT06081894
- Phase
- Phase 3
The FDA approved Aficamten on 19 Dec 2025.
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)NCT06081894 | Cytokinetics | Phase 3 | Active not recruiting | 2026-08-31Actual |
| A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).NCT06412666 | Cytokinetics | Phase 2, Phase 3 | Active not recruiting | 2030-01Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2025-12-19Day | Aficamten | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA219083", "applicant_as_listed_by_fda": "CYTOKINETICS", "brand_names": ["MYQORZO"], "active_ingredients": ["AFICAMTEN"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20251219", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |